October 7, 2005
The Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, Massachusetts 02115
Agenda
| 7:30 am | Registration and Continental Breakfast |
| 8:00 | Opening Comments Keith F. Batchelder, MD; CEO, Genomic Healthcare Strategies David Resnick, JD; Partner, Nixon Peabody |
| 8:15 | Keynote Address: Dr. Judah Folkman: Can Cancer Be Treated Before It Can Be Anatomically Located? Dr. Judah Folkman, Children’s Hospital; Director, Vascular Biology Program Harvard Medical School; Andrus Professor of Pediatric Surgery and Professor of Cell Biology |
| 9:15 | Session 1 Organizational Involvement in Personalized Medicine Session moderated by Keith F. Batchelder, MD; CEO, Genomic Healthcare Strategies Panelists: Mara Aspinall, President, Genzyme Genetics; Barry Zallen, MD, Medical Director, Blue Cross Blue Shield of Massachusetts; Robert Jevon, Partner, Boston Millenia Partners; David Margulies, MD, CEO, Correlagen, Inc.; Victoria Richon, PhD, Senior Director, Cancer Biology and Therapeutics, Merck; Harold J. Burstein, MD, PhD, Assistant Professor of Medicine, Harvard Medical School; Tom Delbanco, MD, Professor of General Medicine and Primary Care, Harvard Medical School |
| 10:30 | Break |
| 10:45 | Session 2 Bringing Personalized Medicine to Market Session moderated by Edward Abrahams, PhD; Executive Director, Personalized Medicine Coalition |
| 11:00 | Intellectual Property Implications of Personalized Medicine “Protecting Personalized Medicine IP Today and In the Future”—David Resnick, JD; Partner, Nixon Peabody “University Research and Personalized Medicine ”—Lita Nelsen, MS; Director, Technology Licensing Office, MIT |
| 11:15 | When the Patient Becomes the Consumer “Consumer Adoption of Personalized Medicine”—Donna Marino, Principal, Genomic Healthcare Strategies “Consumer Genomic Diagnostic Tests”—Philip Reilly, MD, JD; CEO, InterLeukin Genetics |
| 11:30 | Pathways to Personalized Medicine “The Path to Combining Diagnosis & Therapy”—Keith Batchelder, MD; CEO, Genomic Healthcare Strategies “The Path to Payment and Economic Success”—Peter Miller, Principal, Genomic Healthcare Strategies |
| 11:45 | Closing Remarks Keith F. Batchelder MD; CEO, Genomic Healthcare Strategies |